Norrsken Mind funds first phase of a European initiative on early access to psychedelic therapies

Norrsken Mind is funding the first phase of work to design the European Early Access Coordination Initiative, a collaboration between the OPEN Foundation and the Psychedelic Access and Research European Alliance (PAREA). The initiative aims to build a coordinated European approach to early access to psychedelic therapies. It is led by Ray Yang, Operations and Project Manager at the OPEN Foundation.

Early access routes, such as compassionate use programmes, allow national regulators to authorise the use of a medicine before it has marketing authorisation. Outside clinical trials, they are one of the few regulated ways patients in Europe with difficult-to-treat mental health conditions can receive psychedelic therapy. Only a few European countries have set up such programmes so far. Each was developed separately, for different patient groups and through different legal mechanisms.

As a result, a country considering early access today has little practical guidance to work from. There is no map of the legal routes available, no benchmark for how long the process takes, and no template for an application. Without coordination, each country risks starting from scratch and facing the same obstacles alone.

The European Early Access Coordination Initiative aims to build a coordinated European approach to early access. It maps the early access routes available across Europe, draws lessons from programmes already running, and supports countries that want to explore and set up their own programmes. It also aims to build a shared library of resources, such as documents from previous applications, so that each new effort can build on the work of those before it.

The initiative also works towards a shared European approach to collecting real-world data, so that experience from early access adds to a common evidence base for clinicians, researchers, regulators and payers. This complements our separate request for proposals for a pan-European patient registry for psychedelic therapies.

Regulatory approval alone does not guarantee access, and health systems are not yet prepared to deliver these therapies. By connecting national efforts and strengthening the evidence base, the initiative intends to help ensure that, where PTs become available, they reach patients with unmet needs safely.

About Norrsken Mind

Norrsken Mind is a non-profit foundation and a leading funder of psychedelic science in Europe. By mobilising philanthropic capital, offering grants, and facilitating partnerships, Norrsken Mind aims to create the conditions for psychedelic treatments to be rigorously studied, responsibly implemented, and ultimately accessible to patients in need.

Contact

Ray Yang: ray@open-foundation.org

More reading